Derved kan natalizumab undertrykke inflammatorisk aktivitet på sygdomsstedet og hæmme yderligere rekruttering af immunceller ind i inflammeret væv.
As such, natalizumab may act to suppress inflammatory activity present at the disease site, and inhibit further recruitment of immune cells into inflamed tissues.